Dr Edmund Njeru Njagi
in Medical Statistics and Cancer Epidemiology
15-17 Tavistock Place
My research work spans the cancer care pathway: routes to diagnosis, access to diagnostic investigations, staging, treatment and related/subsequent outcomes. Disentangling drivers of variation in cancer care and cancer outcomes through robust statistical and epidemiological approaches on large linked national administrative and clinical datasets encapsulates my day-to-day activities.
I am part of the National Cancer Audit Collaborating Centre within the Clinical Effectiveness Unit, long-standing academic collaboration between the London School of Hygiene & Tropical Medicine (LSHTM) and the Royal College of Surgeons of England.
Broadly, I study the quality of, and variation in, cancer care and cancer outcomes in England and Wales, in the context of cancer services research commissioned by the Healthcare Quality Improvement Partnership on behalf of the National Health Service England and the Welsh Government. I previously worked with the Inequalities in Cancer Outcomes Network at LSHTM on Cancer Research UK-funded studies on variation in cancer care and cancer outcomes in England.
I trained in Biostatistics at Universiteit Hasselt in Belgium within the Interuniversity Institute for Biostatistics and statistical Bioinformatics, where I obtained my PhD in Biostatistics focusing on statistical methodology for longitudinal and missing data analysis, and where I subsequently consulted for the European Food Safety Authority.
Internationally, I regularly speak on the topic of missing data and multiple imputation in cancer epidemiology for the biennial Corsican Summer School on Modern Methods in Biostatistics and Epidemiology in France. I have also had invited engagements at Stellenbosch University in Cape Town and the University of Nairobi, ranging from invited lectures to research supervision.
Variation/inequalities in cancer care and cancer outcomes, focusing on breast cancer (primary and metastatic), ovarian, pancreatic, non-Hodgkin lymphoma and kidney cancer.